Also trades as: BFRI (NASDAQ) · $vol 0M
BFRIW NASDAQ
Biofrontera Inc.
1W: -66.2%
1M: -72.5%
3M: -89.2%
YTD: -92.0%
1Y: -93.5%
3Y: -99.5%
$0.01
-0.00 (-30.61%)
Weekly Expected Move ±28.0%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$3.9M
52W Range0.0068-0.1484
Volume116
Avg Volume3,749
Beta0.80
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOHermann Lübbert
Employees92
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2021-10-29
Websitebiofrontera-us.com
660 Main Street
Woburn, MA 01801
US
Woburn, MA 01801
US
781-245-1325
About Biofrontera Inc.
Biofrontera Inc. is a biopharmaceutical firm specializing in the commercialization of pharmaceutical solutions for skin-related ailments across the United States. Its product lineup features Ameluz, a prescription drug employed with the BF-RhodoLED lamp series for photodynamic therapy. This treatment is designed for both localized and broader area management of mild-to-moderate actinic keratosis on the face and scalp. Additionally, the company offers Xepi, a topical, non-fluorinated quinolone that functions by inhibiting bacterial growth to treat impetigo. Established in 2015, Biofrontera Inc. is headquartered in Woburn, Massachusetts.
Latest News
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Luebbert Hermann | M-Exempt | 137,500 | — | 2026-03-05 |
| Luebbert Hermann | M-Exempt | 137,500 | — | 2026-03-05 |
| Leffler Eugene Frede | M-Exempt | 87,500 | — | 2026-03-05 |
| Leffler Eugene Frede | M-Exempt | 87,500 | — | 2026-03-05 |
| Luebbert Hermann | A-Award | 125,000 | — | 2026-03-04 |